Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i
Lambert, Veronique, Kane, Sarah, Howidi, Belal, Nguyen, Bao-Ngoc, Chandiwana, David, Wu, Yan, Edwards, Michelle, Samjoo, Imtiaz A
Published in BMC cancer (23.05.2024)
Published in BMC cancer (23.05.2024)
Get full text
Journal Article
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
Amdahl, Jordan, Diaz, Jose, Sharma, Arati, Park, Jinhee, Chandiwana, David, Delea, Thomas E
Published in PloS one (21.06.2017)
Published in PloS one (21.06.2017)
Get full text
Journal Article
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
Fasching, Peter A., Beck, J. Thaddeus, Chan, Arlene, De Laurentiis, Michele, Esteva, Francisco J., Jerusalem, Guy, Neven, Patrick, Pivot, Xavier, Bianchi, Giulia V., Martin, Miguel, Chandiwana, David, Lanoue, Brad, Ridolfi, Antonia, Wang, Yingbo, Rodriguez Lorenc, Karen, Nusch, Arnd
Published in Breast (Edinburgh) (01.12.2020)
Published in Breast (Edinburgh) (01.12.2020)
Get full text
Journal Article
Web Resource
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
Harbeck, Nadia, Franke, Fabio, Villanueva-Vazquez, Rafael, Lu, Yen-Shen, Tripathy, Debu, Chow, Louis, Babu, Govind K, Im, Young-Hyuck, Chandiwana, David, Gaur, Anil, Lanoue, Brad, Rodriguez-Lorenc, Karen, Bardia, Aditya
Published in Therapeutic advances in medical oncology (2020)
Published in Therapeutic advances in medical oncology (2020)
Get full text
Journal Article
Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2- advanced breast cancer
Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio
Published in Cancer management and research (01.01.2018)
Published in Cancer management and research (01.01.2018)
Get full text
Journal Article
Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2− advanced breast cancer
Tripathy, Debu, Curteis, Tristan, Hurvitz, Sara, Yardley, Denise, Franke, Fabio, Babu, K. Govind, Wheatley-Price, Paul, Im, Young-Hyuck, Pencheva, Radost, Eddowes, Lucy A., Dionne, Pierre-Alexandre, Chandiwana, David, Pathak, Purnima, Lanoue, Brad, Harbeck, Nadia
Published in Therapeutic advances in medical oncology (01.02.2022)
Published in Therapeutic advances in medical oncology (01.02.2022)
Get full text
Journal Article
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang
Published in Breast cancer research and treatment (01.08.2018)
Published in Breast cancer research and treatment (01.08.2018)
Get full text
Journal Article
Real-world outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and tumors harboring androgen receptor ( AR ) ligand-binding domain (LBD) mutations
Stewart, Tyler F., Chandiwana, David, Doyle, Ashley, Boame, Nana, Saha, Jayati, Zhang, Nicole, Benjumea, Darrin, Rava, Andrew, Parameswaran, Janaki, Edwards, Michelle L., Lang, Joshua Michael
Published in Journal of clinical oncology (01.02.2024)
Published in Journal of clinical oncology (01.02.2024)
Get full text
Journal Article
Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2
Cameron, David, Kumar Sharma, Vikash, Biswas, Chandroday, Clarke, Cathy, Chandiwana, David, Pathak, Purnima
Published in Journal of medical economics (31.12.2023)
Published in Journal of medical economics (31.12.2023)
Get full text
Journal Article
Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
Turner, Stuart, Chia, Stephen, Kanakamedala, Hemanth, Hsu, Wei‐Chun, Park, Jinhee, Chandiwana, David, Ridolfi, Antonia, Yu, Chu‐Ling, Zarate, Juan Pablo, Rugo, Hope S.
Published in The oncologist (Dayton, Ohio) (01.07.2021)
Published in The oncologist (Dayton, Ohio) (01.07.2021)
Get full text
Journal Article
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective
Stellato, Daniel, Thabane, Marroon E., Park, Jinhee, Chandiwana, David, Delea, Thomas E.
Published in PharmacoEconomics (01.09.2021)
Published in PharmacoEconomics (01.09.2021)
Get full text
Journal Article
Real-world incidence, duration, and severity of treatment-emergent (TE) neutropenia among patients (pts) with metastatic breast cancer (MBC) treated with ribociclib (RIB) or palbociclib (PAL)
Schwartzberg, Lee S., Zarate, Juan Pablo, Chandiwana, David, Yu, Chu-Ling, Balu, Sanjeev, Kanakamedala, Hemanth, Turner, Stuart J
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective
Stellato, Daniel, Thabane, Marroon E., Chandiwana, David, Park, Jinhee, Delea, Thomas E.
Published in PharmacoEconomics (01.07.2021)
Published in PharmacoEconomics (01.07.2021)
Get full text
Journal Article
Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC)
Tripathy, Debu, Curteis, Tristan, Hurvitz, Sara A., Yardley, Denise A., Franke, Fabio, Kanakasetty, Govind Babu, Wheatley-Price, Paul, Im, Young-Hyuck, Pencheva, Radost, Chandiwana, David, Pathak, Purnima, Lanoue, Brad, Harbeck, Nadia
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis
Ayyagari, Rajeev, Tang, Derek, Patterson-Lomba, Oscar, Zhou, Zhou, Xie, Jipan, Chandiwana, David, Dalal, Anand A, Niravath, Polly Ann
Published in Current medical research and opinion (02.09.2018)
Published in Current medical research and opinion (02.09.2018)
Get more information
Journal Article
Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis
Ayyagari, Rajeev, Tang, Derek, Patterson-Lomba, Oscar, Zhou, Zhou, Xie, Jipan, Chandiwana, David, Dalal, Anand A, Niravath, Polly Ann
Published in Clinical therapeutics (01.04.2018)
Published in Clinical therapeutics (01.04.2018)
Get full text
Journal Article
Abstract P1-19-06: Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer
Harbeck, Nadia, Hurvitz, Sara, Bardia, Aditya, Franke, Fabio, Babu, K. Gonvind, Wheatley-Price, Paul, Im, Young-Hyuck, Altundag, Kadri, Ridolfi, Antonia, Chandiwana, David, Lanoue, Brad, Menon, Lakshmi, Tripathy, Debu
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article